Emerging antithrombotic agents: What does the intensivist need to know?

Current Opinion in Critical Care

Volumn 16, Issue 5, 2010, Pages 419-425

  Iqbal, Zafar ^a   Cohen, Marc ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Antithrombotic therapy; Cardiovascular diseases

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; OTAMIXABAN; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; RISK FACTOR; THROMBOSIS PREVENTION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

FIBRINOLYTIC AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALISTS; HUMANS; INTENSIVE CARE UNITS;

EID: 78449281862     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32833e1092     Document Type: Review

References (38)

1. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemostasis 2003; 1:1602-1612.
2. Martinelli I, Bucciarelli P, Mannuccio P. Thrombotic risk factors: basic pathophysiology. Crit Care Med 2010; 38 (Suppl):S3-S9.
3. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121:1523-1532.
4. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010; 121:569-583.
5. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2010. Art. No.: CD003747. doi 10.1002/14651858.CD003747.pub3.
6. Cheng S, Morrow DA, Sloan S. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation 2009; 119:1195-1202.
7. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477-1488.
8. Joel M. Gore, Frederick A. Spencer, Robert J. Goldberg, et al. Use of heparins in non-ST-elevation acute coronary syndromes. Am J Med 2007; 120:63-71.
9. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45-54.
10. Cohen M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY Trial: Enoxaparin Versus Unfractionated Heparin in Non-ST-segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol 2006; 48:1346-1354.
11. Cohen M, Mahaffey KW, Levine GL, et al. Enoxaparin 0.3 mg/kg iv supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial. Cath Cardiovasc Interven 2010. [Epub ahead of print]
12. Montalescot G, Gallo R, White HD, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention: 1-year results from the STEEPLE trial. J Am Coll Cardiol Interv 2009; 2:1083-1091.
13. Jolly SS, Faxon DP, Fox KAA, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycopro-tein Ilb/IIIa inhibitors or thienopyridines: results from the OASIS 5 trial. J Am Coll Cardiol 2009; 54:468-476.
14. Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009. doi 10.1016/S0140-6736(09)61454-9.
15. Alexander JH, Becker RC, Bhatt DL, Cools F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119:2877-2885.
16. Mega J, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double blind, phase II trial. Lancet 2009; 374:29-38.
17. Study of Apixaban for the Prevention of Thrombosis-related Events in Patients with Acute Medical Illness (ADOPT). http://clinicaltrials.gov/ct2/show/ NCT00457002. [Accessed 3 November 2009]
18. Efficacy and safety study of apixaban for extended treatment of deep vein thrombosis or pulmonary embolism. http://clinicaltrials.gov/ct2/show/ NCT00633893. [Accessed 3 November 2009]
19. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009; 373:1673-1680.
20. Shantsila E, Lip GYH, Chong BH. Heparin-induced thrombocytopenia: a contemporary clinical approach to diagnosis and management. Chest 2009; 135:1651-1664.
21. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230.
22. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688-696.
23. Schulz S, Mehilli L, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010; 31:582-587.
24. Cohen M. The thrombin hypothesis in ACS: a disappointing disconnect between bench data and bedside clinical ACS trials. Am J Med 2010; 123:103-110.
25. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
26. Giugliani RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009; 360:1-15.
27. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009; 30:2705-2713.
28. Mehta SR, Bassand JP, Chrolavicius S, et al. CURRENTOASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Presented at the European Society of Cardiology Congress, Barcelona, Spain, August 2009.
29. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK. 2007 ACC/AHA/SCAI PCI Focused Update. J Am Coll Cardiol 2008; 51:172-209.
30. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.
31. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374:989-997.
32. Clopidogrel and the optimization of gastro-intestinal events trial (COGENT trial). Presented by Bhatt D at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2009), San Francisco, California, September 24 2009.
33. Montalescot G, Wiviott SD, Braunwald E, et al. TRITON TIMI-38: STEMI. Lancet 2009; 373:723-731.
34. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375:283-293.
35. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO trial. Presented at ACC, March 16th 2010.
36. Fox KAA, Carruthers K, Steg PG, et al. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? GRACE Registry. Eur Heart J 2010; 31:667-675.
37. Tsai T, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302:2458-2464.
38. Cohen M, Alexander KP, Rao SV. Bleeding after anti thrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? J Thrombosis Thrombolysis 2008; 26:175-182.